Oct.01 -- Merck & Co.’s Covid-19 antiviral pill molnupiravir reduced the risk of hospitalization or death by 50% in an interim analysis of a late-stage trial, findings that could give doctors another potent virus-fighting tool. Johns Hopkins Bloomberg School of Public Health Professor and Virologist Andrew Pekosz is on "Bloomberg Surveillance." The Bloomberg School of Public Health is supported by Michael R. Bloomberg, founder and majority owner of Bloomberg LP, the parent company of Bloomberg News.
